SCHEDULE 13G/A
0001104659-24-119407
0002042634
XXXXXXXX
LIVE
1
Common stock, par value $0.0001 per share
12/13/2024
0001870404 CERO THERAPEUTICS HOLDINGS, INC. 71902K105
201 Haskins Way, Suite 230
South San Francisco
CA
94080
Rule 13d-1(c)
YK Bioventures Opportunities GP I, LLC
DE
0.00
17002.00
0.00
17002.00
17002.00
0.0
OO
YK Bioventures Opportunities Fund I, L.P.
DE
0.00
17002.00
0.00
17002.00
17002.00
0.0
PN
Gary K. Yeung
X1
0.00
17002.00
0.00
17002.00
17002.00
0.0
IN
Mitchell W. Kossar
X1
0.00
17002.00
0.00
17002.00
17002.00
0.0
IC
IN
CERO THERAPEUTICS HOLDINGS, INC.
201 Haskins Way, Suite 230, , South San Francisco, CA, 94080.
The names of the persons filing this report (collectively, the "Reporting Persons") are:
1. YK Bioventures Opportunities GP I, LLC (the "General Partner")
2. YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (the "Fund")
3. Gary Yeung
4. Mitchell Kossar
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. c/o YK Bioventures Capital Partners, LLC, 398 Primrose Road, Suite 328, Burlingame, CA 94010. The General Partner is a Delaware limited liability company and the Fund is a Delaware limited partnership. Messrs. Yeung and Kossar are United States citizens.
Y
The information required by this item with respect to each Reporting Person is set forth in Row 9 of the Reporting Person Information pages to this Schedule 13G.
As of December 17, 2024, the Fund directly holds 17,002 shares of Common Stock of the Issuer. The General Partner is the general partner of the Fund. Messrs. Yeung and Kossar are the managing partners of the General Partner. As the general partner of the Fund, the General Partner may be deemed to beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"), any securities of the Issuer held by the Fund. As managing partners of the General Partner, Messrs. Yeung and Kossar may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund.
The information required by this item with respect to each Reporting Person is set forth in Row 11 of the Reporting Person Information pages to this Schedule 13G. The ownership percentages reported are based upon 191,881,107 shares of Common Stock outstanding as of December 16, 2024, as reported to the Reporting Persons by the Issuer.
The information required by this item with respect to each Reporting Person is set forth in Row 5 of the Reporting Person Information pages to this Schedule 13G.
The information required by this item with respect to each Reporting Person is set forth in Row 6 of the Reporting Person Information pages to this Schedule 13G.
The information required by this item with respect to each Reporting Person is set forth in Row 7 of the Reporting Person Information pages to this Schedule 13G.
The information required by this item with respect to each Reporting Person is set forth in Row 8 of the Reporting Person Information pages to this Schedule 13G.
N
Y
Y
Y
Y
Y
N
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Exhibit 99.1 Joint Filing Agreement
YK Bioventures Opportunities GP I, LLC
/s/ Gary K. Yeung
12/17/2024
YK Bioventures Opportunities Fund I, L.P.
/s/ Gary K. Yeung
12/17/2024
Gary K. Yeung
/s/ Gary K. Yeung
12/17/2024
Mitchell W. Kossar
/s/ Mitchell W. Kossar
12/17/2024